CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance.
Emerging evidence indicates the presence of tumor-initiating cells (TIC) or cancer stem cells in osteosarcoma. However, no study has shown specific markers to identify osteosarcoma TICs with in vivo tumor formation ability. Additionally, there has been a lack of investigations gauging the contribution of osteosarcoma TICs to metastatic and drug-resistant properties. In this study, we have identified mouse and human osteosarcoma TICs using mesenchymal stem cell markers CD117 and Stro-1. These markers were preferentially expressed in spheres and doxorubicin-resistant cells. Both mouse and human cells expressing these markers were sorted and analyzed for their abilities of tumor formation with as few as 200 cells, self-renewability, multipotency, drug resistance, metastatic potential, and enrichment of a metastasis-associated marker (CXCR4) and a drug resistance marker (ABCG2). CD117(+)Stro-1(+) cells efficiently formed serially transplantable tumors, whereas CD117(-)Stro-1(-) cells rarely initiated tumors. On orthotopic injections, CD117(+)Stro-1(+ )cell-derived tumors metastasized at a high frequency. Further, CD117(+)Stro-1(+) cells showed high invasive and drug-resistant properties and were efficiently enriched for CXCR4 (20-90%) and ABCG2 (60-90%). These results suggest possible mechanisms for the high metastatic and drug-resistant properties of osteosarcoma TICs. In summary, CD117 and Stro-1 identify osteosarcoma TICs associated with the most lethal characteristics of the disease-metastasis and drug resistance-and these markers offer candidates for TIC-targeted drug delivery aimed at eradicating osteosarcoma.
Adhikari
Amit S
AS
Departments of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Agarwal
Neeraj
N
Wood
Byron M
BM
Porretta
Constance
C
Ruiz
Bernardo
B
Pochampally
Radhika R
RR
Iwakuma
Tomoo
T
D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000378:metabolism; D000328:Adult; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000954:Antigens, Surface / Q000378:metabolism*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D051379:Mice; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000378:metabolism; D012516:Osteosarcoma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000378:metabolism
C116614:ABCG2 protein, human; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; C501412:Abcg2 protein, mouse; D000903:Antibiotics, Antineoplastic; D000954:Antigens, Surface; C527276:CXCR4 protein, human; C514936:CXCR4 protein, mouse; D009363:Neoplasm Proteins; D019718:Receptors, CXCR4; C525591:STRO-1 antigen, human; C525590:STRO-1 antigen, mouse; D004317:Doxorubicin; D019009:Proto-Oncogene Proteins c-kit
Oncogene. 2007 Feb 26;26(9):1357-60
17322922
Oncogene. 2004 Sep 20;23(43):7274-82
15378087
Cancer Res. 2007 May 15;67(10):4827-33
17510412
PLoS One. 2008;3(10):e3469
18941626
Med Pediatr Oncol. 1998 Dec;31(6):471-4
9835898
Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33
15381773
Cell. 2004 Dec 17;119(6):861-72
15607981
Blood. 2002 Jan 15;99(2):507-12
11781231
Int J Oncol. 2009 May;34(5):1381-6
19360350
Expert Rev Anticancer Ther. 2009 Aug;9(8):1035-49
19671023
Br J Cancer. 2008 Apr 22;98(8):1389-97
18349830
Clin Cancer Res. 2005 Apr 1;11(7):2561-7
15814634
Clin Cancer Res. 2004 Mar 1;10(5):1691-7
15014021
Nat Med. 1997 Jul;3(7):730-7
9212098
Cell Cycle. 2007 Nov 15;6(22):2782-7
17998803
Nat Rev Cancer. 2005 Nov;5(11):899-904
16327766
J Tissue Eng Regen Med. 2008 Mar-Apr;2(2-3):147-54
18383557
J Orthop Res. 2006 Jan;24(1):21-8
16419965
Nature. 2004 Nov 18;432(7015):396-401
15549107
Acta Pol Pharm. 2008 Jul-Aug;65(4):493-500
19051593
Blood. 1994 Dec 15;84(12):4164-73
7994030
Exp Cell Res. 2006 Nov 15;312(19):3701-10
17046749
Mod Pathol. 2006 May;19(5):738-45
16528367
Nature. 2008 Jan 17;451(7176):345-9
18202660
Oncogene. 2001 Jul 5;20(30):4041-9
11494132
Cell Stem Cell. 2007 Sep 13;1(3):313-23
18371365
Clin Cancer Res. 2006 Oct 1;12(19):5615-21
17020963
Leukemia. 2002 Aug;16(8):1443-7
12145683
Environ Health Perspect. 1983 Nov;53:155-61
6363051
Clin Exp Metastasis. 2000;18(3):261-71
11315100
J Cell Physiol. 2009 May;219(2):301-13
19160414
Biomed Pharmacother. 2006 Jul;60(6):273-6
16828253
Nature. 2001 Nov 1;414(6859):105-11
11689955
Int J Cancer. 2007 Jun 1;120(11):2510-6
17294449
J Int Med Res. 2008 Sep-Oct;36(5):1008-14
18831895
Nature. 2007 Jan 4;445(7123):106-10
17122772
J Endocrinol Invest. 2008 Sep;31(9):809-19
18997494
Mol Cancer. 2006 Dec 02;5:67
17140455
Oncogene. 2008 Mar 20;27(13):1813-20
17906694
Clin Cancer Res. 2010 Jan 1;16(1):45-55
20028757
Neurosurg Focus. 2008;24(3-4):E28
18341405
J Clin Pathol. 2007 Jul;60(7):804-7
17018686
J Clin Oncol. 2005 Apr 1;23(10):2248-55
15800315
Neoplasia. 2005 Nov;7(11):967-76
16331882